Celularity Inc. Class A (CELU)
NASDAQ: CELUHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CELU stock chart
Technical analysisKey statistics
All statistics- Market cap
- $15.02M
- EPS (TTM)
- -$1.69
- Dividend yield
- None
- 52-week range
- 0.42 – 2.55
- Day range
- 0.4202 – 0.4999
- Volume / Avg
- 295.91K / 3.95M
- Beta
- —
- Shares outstanding
- 32.45M
52-week range
CELU stock today
Celularity (CELU) closed at $0.463 on Nov 20, down 1.05% (-$0.0049), versus the S&P 500's 3.70% decline. Trading was light, with 295.91K shares changing hands, about 7% of the average daily volume. Shares are 81.8% below their 52-week high of $2.55, set on Aug 27, 2026 and 10.2% above the 52-week low of $0.42, near the bottom of the past year's range.
CELU is down 58.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 73.5%. Celularity has posted a net loss over the last twelve months (EPS of -$1.69), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Celularity
Company profileCelularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Robert Joseph Hariri M.D., Ph.D.
- Headquarters
- Florham Park, NJ
- Employees
- 115
- IPO year
- 2019
- Website
- celularity.com
Financial highlights
Full financialsIn fiscal 2025, Celularity generated $26.6 million in revenue, down 51.0% from fiscal 2024, its first annual decline since 2022. Celularity reported a net loss of $91.7 million, compared with a loss of $57.9 million a year earlier. Gross margin was 24.4% (down from 72.4%) and operating margin -230.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $26.55M | $54.22M | $22.77M | $17.98M | $21.34M |
| Growth | -51.03% | +138.11% | +26.68% | -15.75% | +49.43% |
| Net income | $-91.72M | $-57.89M | $-196.29M | $14.19M | $-100.12M |
| EPS (diluted) | $-3.59 | $-2.64 | $-11.02 | $0.95 | $-1.49 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 20, 2026
- EPS actual vs est.
- $-0.88 vs —
CELU news
All CELU newsCelularity peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CNTXContext Therapeutics Inc. | 0.16 | -5.10% | $14.70M | vs CELU |
| NCELNewcelX Ltd. | 2.54 | -5.58% | $14.67M | vs CELU |
| QNRXQuoin Pharmaceuticals Ltd. ADR | 3.28 | -2.35% | $15.76M | vs CELU |
| PBMPsyence Biomedical Ltd. | 2.97 | +3.85% | $15.80M | vs CELU |
| ATOSAtossa Therapeutics Inc. | 1.60 | -8.86% | $15.92M | vs CELU |
| LPCNLipocine Inc. | 1.48 | -1.33% | $16.39M | vs CELU |
| CTXRCitius Pharmaceuticals Inc. | 0.5085 | +2.27% | $13.96M | vs CELU |
| SHPHShuttle Pharmaceuticals Holdings Inc. | 3.49 | -10.51% | $16.63M | vs CELU |
Indexes, lists and sector
Celularity stock FAQ
What is Celularity's stock price today?
CELU last traded at $0.463 as of Nov 20, 4:00 PM EST, down 1.05% on the day. Prices are delayed at least 15 minutes.
Does Celularity pay a dividend?
No. Celularity does not currently pay a regular cash dividend.
Who is Celularity's CEO?
Dr. Robert Joseph Hariri M.D., Ph.D. is the chief executive officer of Celularity Inc. Class A, which has about 115 employees.
Has CELU ever split its stock?
Yes. The most recent CELU stock split was a 1-for-10 split on Feb 29, 2024.
What is the CELU 52-week high?
The 52-week high for CELU is $2.55 and the 52-week low is $0.42. The stock is currently 81.8% below its high.